Choline elevation in amygdala region at recovery indicates longer survival without depressive episode: a magnetic resonance spectroscopy study
| Autor: | Tamara Foro, Maja Bajs Janović, Viktorija Erdeljić Turk, Petra Kalember, Neven Henigsberg, David Ozretić, Pero Hrabač, Helena Šarac, Ana Šečić, Marko Radoš, Aleksandar Savić, Milan Radoš |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty Cho Proton Magnetic Resonance Spectroscopy Lower risk Gastroenterology Amygdala Glx Choline 03 medical and health sciences 0302 clinical medicine Maintenance therapy Recurrence Recovery Internal medicine Magnetic resonance spectroscopy medicine Humans Depression (differential diagnoses) Original Investigation Pharmacology NAA Aspartic Acid business.industry Depression Repeated measures design Brain Antidepressants Middle Aged Magnetic Resonance Imaging Confidence interval Antidepressive Agents 030227 psychiatry Discontinuation medicine.anatomical_structure Antidepressant Therapy business 030217 neurology & neurosurgery |
| Zdroj: | Psychopharmacology |
| DOI: | 10.1007/s00213-019-05303-2 |
| Popis: | Rationale Depression, with variable longitudinal patterns, recurs in one third of patients. We lack useful predictors of its course/outcome, and proton magnetic resonance spectroscopy (1H-MRS) of brain metabolites is an underused research modality in finding outcome correlates. Objectives To determine if brain metabolite levels/changes in the amygdala region observed early in the recovery phase indicate depression recurrence risk in patients receiving maintenance therapy. Methods Forty-eight patients on stable-dose antidepressant (AD) maintenance therapy were analyzed from recovery onset until (i) recurrence of depression or (ii) start of AD discontinuation. Two 1H-MRS scans (6 months apart) were performed with a focus on amygdala at the beginning of recovery. N-acetylaspartate (NAA), choline-containing metabolites (Cho), and Glx (glutamine/glutamate and GABA) were evaluated with regard to time without recurrence, and risks were assessed by Cox proportional hazard modeling. Results Twenty patients had depression recurrence, and 23 patients reached AD discontinuation. General linear model repeated measures analysis displayed three-way interaction of measurement time, metabolite level, and recurrence on maintenance therapy, in a multivariate test, Wilks’ lambda = 0.857, F(2,40) = 3.348, p = 0.045. Cho levels at the beginning of recovery and subsequent changes convey the highest risk for earlier recurrence. Patients experiencing higher amygdala Cho after recovery are at a significantly lower risk for depression recurrence (hazard ratio = 0.32; 95% confidence interval 0.13–0.77). Conclusion Cho levels/changes in the amygdala early in the recovery phase correlate with clinical outcome. In the absence of major NAA fluctuations, changes in Cho and Glx may suggest a shift towards reduction in (previously increased) glutamatergic neurotransmission. Investigation of a larger sample with greater sampling frequency is needed to confirm the possible predictive role of metabolite changes in the amygdala region early in the recovery phase. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|